ReviewExpert review of gastroenterology & hepatology2011
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.
Review in Expert review of gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 250 citations in OpenAlex.
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight · 2020Trial
- The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease.PloS one · 2016Trial
- Melatonin Promotes Improvement in Serum Lipid Levels and Liver Histopathology in Hyperlipidemic Rats.Lipids · 2026Article
- Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Primary, Secondary and Exploratory Endpoints in Phase 2 and 3 Clinical Trials with Novel Therapies in MASH Cirrhosis: A Systematic Review.Journal of clinical medicine · 2026Review
- Pesticides Drive Liver Diseases Through Non-Apoptotic Regulated Cell Death Pathways.Diseases (Basel, Switzerland) · 2026Review
- Hepatocyte-Derived Apoptotic Bodies as Pathological Intercellular Messengers in the Liver.Biomolecules · 2026Review
- Fatty Liver in Fish: Metabolic Drivers, Molecular Pathways and Physiological Solutions.Animals : an open access journal from MDPI · 2026Review
- Cytokeratin-18 increase as a signal for early liver cell changes in high-fat diet-induced obesity before overt steatohepatitis.Frontiers in endocrinology · 2026Article
- Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Article
- Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.Lipids in health and disease · 2025Review
- Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways.Gastroenterology and hepatology from bed to bench · 2025Article
- A Golden Shield: The Protective Role of Curcumin against Liver Fibrosis.Current medicinal chemistry · 2025Review
- Hepatocyte-specific loss of melanocortin 1 receptor disturbs fatty acid metabolism and promotes adipocyte hypertrophy.International journal of obesity (2005) · 2024Article
- Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.Journal of clinical and translational hepatology · 2024Review
- Contribution of extracellular vesicles to steatosis-related liver disease and their therapeutic potential.World journal of hepatology · 2024Review
- Article
- Observational
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.International journal of pharmaceutics · 2024Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pathological increases in cell death in the liver as well as in peripheral tissues has emerged as an important mechanism involved in the development and progression of nonalcoholic fatty liver disease (NAFLD). An increase in hepatocyte cell death by apoptosis is typically present in patients with NAFLD and in experimental models of steatohepatitis, while an increase in adipocyte cell death in visceral adipose tissue may be an important mechanism triggering insulin resistance and hepatic steatosis. The two fundamental pathways of apoptosis, the extrinsic (death receptor-mediated) and intrinsic (organelle-initiated) pathways, are both involved. This article summarizes the current knowledge related to the distinct molecular and biochemical pathways of cell death involved in NAFLD pathogenesis. In particular, it will highlight the efforts for the development of both novel diagnostic and therapeutic strategies based on this knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.